Cite
HARVARD Citation
Madhi, S. et al. (2022). Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. Lancet. 9 (5), pp. e309-e322. [Online].